The use of intravesical BCG in urothelial carcinoma of the bladder

Omar Alhunaidi 1 2, Alexandre R Zlotta 1 3 4

Affiliations

doi: 10.3332/ecancer.2019.905

Abstract

The high recurrence and progression rates of non-muscle invasive bladder cancer (NMIBC) have led investigators to study the use of intravesical therapy in order to prevent them. Bacillus Calmette-Guérin (BCG) has been successfully used for this indication to treat NMIBC for more than four decades. BCG is the only intravesical agent shown to reduce the risk of progression of NMIBC to muscle-invasive disease. Despite over 40 years of clinical use, the precise mechanism of action for what has often been considered the most successful cancer immunotherapy in humans remains largely unknown. Unfortunately, BCG therapy is not a universal panacea and it still fails in up to 40% of patients. Many of these patients, especially in the high-risk category (T1 high-grade disease, carcinoma in situ) will require aggressive therapy like cystectomy or in selected cases, bladder-sparing options like chemo-radiation. Indeed, there is no gold standard intravesical treatment after BCG failure.

Keywords: bacillus Calmette–Guérin; bladder cancer; intravesical therapy; non-muscle invasive bladder cancer; urothelial carcinoma.

Conflict of interest statement

None.

Similar articles

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.PMID: 31200843

Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.

Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE.Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.PMID: 24144432

Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.

Rao MV, Ellimoottil C, Sondej T, Flanigan RC, Quek ML.Urol Oncol. 2013 Aug;31(6):857-61. doi: 10.1016/j.urolonc.2011.07.005. Epub 2011 Aug 24.PMID: 21868262

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28.PMID: 23628309 Review.

Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma.

Yassaie O, Chehroudi C, Black PC.Ther Adv Med Oncol. 2021 Aug 14;13:17588359211039052. doi: 10.1177/17588359211039052. eCollection 2021.PMID: 34408797 Free PMC article. Review.

Cited by

Fibroblast Growth Factor-2 and the Invasive Potential in Urothelial Malignancies of the Bladder.

Popov H, Stoyanov GS, Ghenev P.Cureus. 2023 Jan 24;15(1):e34147. doi: 10.7759/cureus.34147. eCollection 2023 Jan.PMID: 36843751 Free PMC article.

Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with Bacillus Calmette-Guérin.

Uehara T, Watanabe S, Yamaguchi S, Eguchi N, Sakamoto N, Oda Y, Arimura H, Kaku T, Ohishi Y, Mizuno S.Cytotechnology. 2023 Feb;75(1):49-62. doi: 10.1007/s10616-022-00559-7. Epub 2022 Nov 19.PMID: 36713061

Secondary Haemophagocytic Lymphohistiocytosis Syndrome (HLH) After Intravesical Instillation of Bacillus Calmette-Guérin (BCG): A Case Report and Review of the Literature.

Manganas K, Angelara M, Bountzona I, Karamanakos G, Toskas A.Eur J Case Rep Intern Med. 2022 Oct 21;9(10):003395. doi: 10.12890/2022_003395. eCollection 2022.PMID: 36415837 Free PMC article.

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma.

Doroud D, Hozouri H.Iran Biomed J. 2022 Nov 1;26(5):340-9. doi: 10.52547/ibj.3676.PMID: 36369747 Free PMC article.

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis.

Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G.Curr Urol. 2022 Sep;16(3):147-153. doi: 10.1097/CU9.0000000000000072. Epub 2022 Aug 2.PMID: 36204362 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Luca S, Mihaescu T. History of BCG vaccine. MAEDICA (Buchae) 2013;8(1):53–58. - PMC - PubMed
  2.  
    1. Old LJ, Clark DA, Benacerraf B. Effect of bacillus calmette-guerin infection on transplanted tumours in the mouse. Nature. 1959;184(5):291–292. doi: 10.1038/184291a0. - DOI - PubMed
  3.  
    1. Mathé G, Amiel JL, Schwarzenberg L, et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969;1(7597):697–699. doi: 10.1016/S0140-6736(69)92648-8. - DOI - PubMed
  4.  
    1. Morton DL, Eilber FR, Joseph WL, et al. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg. 1970;172(4):740–749. doi: 10.1097/00000658-197010000-00018. - DOI - PMC - PubMed
  5.  
    1. Zbar B, Bernstein I, Tanaka T, et al. Tumor immunity produced by the intradermal inoculation of living tumor cells and living mycobacterium bovis (strain BCG) Science. 1970;170(3963):1217–1218. doi: 10.1126/science.170.3963.1217. - DOI - PubMed
  6.  
    1. Zbar B, Ribi E, Rapp HJ. An experimental model for immunotherapy of cancer. Natl Cancer Inst Monogr. 1973;39:3–9. - PubMed
  7.  
    1. Bloomberg SD, Brosman SA, Hausman MS, et al. The effects of BCG on the dog bladder. Invest Urol. 1975;12(6):423–427. - PubMed
  8.  
    1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette-guérin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183. doi: 10.1016/S0022-5347(17)58737-6. - DOI - PubMed
  9.  
    1. Lamm DL, Thor DE, Harris SC, et al. Bacillus calmette-guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–40. doi: 10.1016/S0022-5347(17)55282-9. - DOI - PubMed
  10.  
    1. Brosman SA. Experience with bacillus calmette-guérin in patients with superficial bladder carcinoma. J Urol. 1982;128(1):27–30. doi: 10.1016/S0022-5347(17)52736-6. - DOI - PubMed
  11.  
    1. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64. doi: 10.5489/cuaj.777. - DOI - PMC - PubMed
  12.  
    1. Fuge O, Vasdev N, Allchorne P, et al. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79. - PMC - PubMed
  13.  
    1. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15:616–625. doi: 10.1038/s41585-018-0055-4. - DOI - PubMed
  14.  
    1. Joudi FN, Smith BJ, O’Donnell MA, et al. Final results from a national multicenter phase II trial of combination bacillus calmette-guérin plus interferon. Urol Oncol. 2006;24(4):344–348. doi: 10.1016/j.urolonc.2005.11.026. - DOI - PubMed
  15.  
    1. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3:S199–S205. doi: 10.5489/cuaj.1196. - DOI - PMC - PubMed
  16.  
    1. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol. 2014;11(3):153–162. doi: 10.1038/nrurol.2014.15. - DOI - PubMed
  17.  
    1. Zlotta AR, Drowart A, Van Vooren JP, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus calmette-guerin during intravesical treatment of superficial bladder cancer. J Urol. 1997;157(2):492–498. doi: 10.1016/S0022-5347(01)65185-1. - DOI - PubMed
  18.  
    1. Zhao W, Schorey JS, Groger R, et al. Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem. 1997;274(8):4521–4526. doi: 10.1074/jbc.274.8.4521. - DOI - PubMed
  19.  
    1. Zlotta AR, Van Vooren JP, Denis O, et al. What are the immunologically active components of bacille calmette-guérin in therapy of superficial bladder cancer? Int J Cancer. 2000;87(6):844–852. - PubMed
  20.  
    1. LaRue H, Ayari C, Bergeron A, et al. Toll-like receptors in urothelial cells—targets for cancer immunotherapy. Nat Rev Urol. 2013;10(9):537–545. doi: 10.1038/nrurol.2013.153. - DOI - PubMed
  21.  
    1. Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V. Treatment of non-muscle invasive bladder cancer with bacillus calmette-guerin (BCG): biological markers and simulation studies. BBA Clin. 2015;4:27–34. doi: 10.1016/j.bbacli.2015.06.002. - DOI - PMC - PubMed
  22.  
    1. Sengiku A, Ito M, Miyazaki Y, et al. A prospective comparative study of intravesical bacillus calmette-guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol. 2013;190(1):50–54. doi: 10.1016/j.juro.2013.01.084. - DOI - PubMed
  23.  
    1. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970. doi: 10.1016/S0022-5347(05)64273-5. - DOI - PubMed
  24.  
    1. Quan Y, Jeong CW, Kwak C, et al. Dose, duration and strain of bacillus calmette-guerin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials. Medicine (Baltimore) 2017;96(42):e8300. doi: 10.1097/MD.0000000000008300. - DOI - PMC - PubMed
  25.  
    1. Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197(5):1189–1199. doi: 10.1016/j.juro.2016.12.090. - DOI - PubMed
  26.  
    1. Gan C, Mostafid H, Khan MS, et al. BCG immunotherapy for bladder cancer—the effects of substrain differences. Nat Rev Urol. 2013;10(10):580–588. doi: 10.1038/nrurol.2013.194. - DOI - PubMed
  27.  
    1. Rentsch CA, Birkhäuser FD, Biot C, et al. Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014;66(4):677–688. doi: 10.1016/j.eururo.2014.02.061. - DOI - PubMed
  28.  
    1. Ritz N, Hanekom WA, Robins-Browne R, et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev. 2008;32(5):821–841. doi: 10.1111/j.1574-6976.2008.00118.x. - DOI - PubMed
  29.  
    1. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus calmette-guérin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600. doi: 10.1016/S0022-5347(17)37316-0. - DOI - PubMed
  30.  
    1. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? are six weekly instillations necessary? Eur Urol. 2000;37(4):470–477. doi: 10.1159/000020170. - DOI - PubMed
  31.  
    1. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124–1129. doi: 10.1016/S0022-5347(05)67707-5. - DOI - PubMed
  32.  
    1. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1) Eur Urol. 2017. [07/9/18]. [ https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-muscle-Invas...]
  33.  
    1. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi: 10.1016/j.eururo.2012.10.039. - DOI - PubMed
  34.  
    1. Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance therapy with 3-monthly bacillus calmette-guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol. 2015;68(2):256–262. doi: 10.1016/j.eururo.2015.02.040. - DOI - PubMed
  35.  
    1. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus calmette-guerin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–216. doi: 10.1046/j.1464-410x.2001.02306.x. - DOI - PubMed
  36.  
    1. Han RF, Pan JG. Can intravesical bacillus calmette-guerin reduce recurrence in patients with superficial bladder cancer? a meta-analysis of randomized trials. J Urol. 2006;67(6):1216–1223. doi: 10.1016/j.urology.2005.12.014. - DOI - PubMed
  37.  
    1. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus calmette-guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–490. doi: 10.1111/j.1464-410X.2003.04655.x. - DOI - PubMed
  38.  
    1. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus calmette-guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256. doi: 10.1016/j.eururo.2009.04.038. - DOI - PubMed
  39.  
    1. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus calmette-guérin, and bacillus calmette-guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–773. doi: 10.1016/j.eururo.2009.12.024. - DOI - PMC - PubMed
  40.  
    1. Duchek M, Johansson R, Jahnson S, et al. Bacillus calmette-guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, nordic study. Eur Urol. 2010;57(1):25–31. doi: 10.1016/j.eururo.2009.09.038. - DOI - PubMed
  41.  
    1. Järvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus calmette-guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–265. doi: 10.1016/j.eururo.2009.04.009. - DOI - PubMed
  42.  
    1. Bohle A, Bock PR. Intravesical bacille calmette-guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. J Urol. 2004;63(4):682–686. doi: 10.1016/j.urology.2003.11.049. - DOI - PubMed
  43.  
    1. Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. 1998;66(12):5743–5750. - PMC - PubMed
  44.  
    1. Kamat AM, Flaig TW, Grossman HB, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225–235. doi: 10.1038/nrurol.2015.58. - DOI - PubMed
  45.  
    1. Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–1944. doi: 10.1200/JCO.2015.64.4070. - DOI - PMC - PubMed
  46.  
    1. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35(20):2299–2305. doi: 10.1200/JCO.2016.69.2327. - DOI - PubMed
  47.  
    1. Juvet T, Wallis C, Krimus L, et al. Sequential administration of BCG and electomotive drug administration (EMDA) of mitomycin C (MMC) in non-muscle invasive bladder cancer having previously received intravesical therapy. J Urol. 2018;199(4S):e1230–e1231. doi: 10.1016/j.juro.2018.02.2999. - DOI

Page Navigation